StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)

Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –

IDEXX Laboratories total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

IDEXX Laboratories's total debt was $449.86M at Jun 30, 2026. For fiscal 2025 it was $449.84M, down 27.2% from the year before. The highest annual figure on record is $908.48M in fiscal 2020.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$449.84M-27.2%
FY2024Dec 31, 2024$617.57M-11.5%
FY2023Dec 31, 2023$697.88M-9.3%
FY2022Dec 31, 2022$769.37M-9.5%
FY2021Dec 31, 2021$850.20M-6.4%
FY2020Dec 31, 2020$908.48M+30.0%
FY2019Dec 31, 2019$698.91M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$449.86M-14.3%
Q1 FY2026Mar 31, 2026$449.85M-27.5%
Q4 FY2025Dec 31, 2025$449.84M-27.2%
Q3 FY2025Sep 30, 2025$524.82M-15.9%
Q2 FY2025Jun 30, 2025$524.81M-24.5%
Q1 FY2025Mar 31, 2025$620.73M-10.8%
Q4 FY2024Dec 31, 2024$617.57M-11.5%
Q3 FY2024Sep 30, 2024$623.90M-18.8%
Q2 FY2024Jun 30, 2024$694.86M-10.0%
Q1 FY2024Mar 31, 2024$695.78M-9.8%
Q4 FY2023Dec 31, 2023$697.88M-9.3%
Q3 FY2023Sep 30, 2023$768.80M+1.1%
Q2 FY2023Jun 30, 2023$771.84M+0.5%
Q1 FY2023Mar 31, 2023$771.35M-0.3%
Q4 FY2022Dec 31, 2022$769.37M-9.5%
Q3 FY2022Sep 30, 2022$760.81M-10.8%
Q2 FY2022Jun 30, 2022$768.00M-15.1%
Q1 FY2022Mar 31, 2022$773.38M-14.4%
Q4 FY2021Dec 31, 2021$850.20M-6.4%
Q3 FY2021Sep 30, 2021$853.02M-5.6%
Q2 FY2021Jun 30, 2021$905.06M+29.5%
Q1 FY2021Mar 31, 2021$903.72M–
Q4 FY2020Dec 31, 2020$908.48M–
Q3 FY2020Sep 30, 2020$903.30M–
Q4 FY2019Dec 31, 2019$698.91M–

More IDEXX Laboratories figures

See a number that looks wrong?